{"pmid":32422152,"title":"Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects.","text":["Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects.","J Infect","Chen, Dr Xian","Shan, Yuheng","32422152"],"journal":"J Infect","authors":["Chen, Dr Xian","Shan, Yuheng"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422152","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jinf.2020.05.020","topics":["Treatment"],"weight":1,"_version_":1667159284529496064,"score":9.490897,"similar":[{"pmid":32366290,"pmcid":"PMC7197031","title":"Mesenchymal stem cells as a potential therapy for COVID-19.","text":["Mesenchymal stem cells as a potential therapy for COVID-19.","The outbreak of 2019 novel coronavirus disease (COVID-19) worldwide is becoming rapidly a major concern. The number of severe cases has increased dramatically worldwide, while specific treatment options are scarce. The main pathologic features of severe or critical COVID-19 were consistent with acute lung injure (ALI)/acute respiratory distress syndrome (ARDS), characterized by cellular fibromyxoid exudates, extensive pulmonary inflammation, pulmonary edema, and hyaline membrane formation. Mesenchymal stem cells (MSCs) can balance the inflammatory response and has been mentioned to be effective on ALI/ARDS from both infectious and noninfectious causes previously, presenting an important opportunity to be applied to COVID-19. In this commentary, we summarize the clinical trials of MSCs treatments on ALI/ARDS and raise MSCs as a hopefully alternative therapy for severe or critical COVID-19.","Stem Cell Res Ther","Liu, Shan","Peng, Danyi","Qiu, Huijun","Yang, Ke","Fu, Zhou","Zou, Lin","32366290"],"abstract":["The outbreak of 2019 novel coronavirus disease (COVID-19) worldwide is becoming rapidly a major concern. The number of severe cases has increased dramatically worldwide, while specific treatment options are scarce. The main pathologic features of severe or critical COVID-19 were consistent with acute lung injure (ALI)/acute respiratory distress syndrome (ARDS), characterized by cellular fibromyxoid exudates, extensive pulmonary inflammation, pulmonary edema, and hyaline membrane formation. Mesenchymal stem cells (MSCs) can balance the inflammatory response and has been mentioned to be effective on ALI/ARDS from both infectious and noninfectious causes previously, presenting an important opportunity to be applied to COVID-19. In this commentary, we summarize the clinical trials of MSCs treatments on ALI/ARDS and raise MSCs as a hopefully alternative therapy for severe or critical COVID-19."],"journal":"Stem Cell Res Ther","authors":["Liu, Shan","Peng, Danyi","Qiu, Huijun","Yang, Ke","Fu, Zhou","Zou, Lin"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366290","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1186/s13287-020-01678-8","keywords":["ali","ards","covid-19","mscs"],"topics":["Treatment"],"weight":1,"_version_":1666138496178323456,"score":70.00961},{"pmid":32420049,"pmcid":"PMC7224671","title":"Combating COVID-19 with Mesenchymal Stem Cell therapy.","text":["Combating COVID-19 with Mesenchymal Stem Cell therapy.","The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.","Biotechnol Rep (Amst)","Rajarshi, Keshav","Chatterjee, Aroni","Ray, Shashikant","32420049"],"abstract":["The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients."],"journal":"Biotechnol Rep (Amst)","authors":["Rajarshi, Keshav","Chatterjee, Aroni","Ray, Shashikant"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420049","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.btre.2020.e00467","keywords":["covid-19","cytokines","immunomodulatory","mesenchymal stem cells","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284484407296,"score":70.00961},{"pmid":32281052,"title":"Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.","text":["Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.","\"COVID-19\" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.","Stem Cell Rev Rep","Golchin, Ali","Seyedjafari, Ehsan","Ardeshirylajimi, Abdolreza","32281052"],"abstract":["\"COVID-19\" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing."],"journal":"Stem Cell Rev Rep","authors":["Golchin, Ali","Seyedjafari, Ehsan","Ardeshirylajimi, Abdolreza"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281052","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s12015-020-09973-w","keywords":["covid-19","clinical trials","coronavirus","immunomodulatory","mesenchymal stem cell","stem cell therapy"],"topics":["Treatment"],"weight":1,"_version_":1666138491544666112,"score":66.69044},{"pmid":32387262,"title":"Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment.","text":["Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment.","Drug Discov Today","O'Driscoll, Lorraine","32387262"],"journal":"Drug Discov Today","authors":["O'Driscoll, Lorraine"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387262","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.drudis.2020.04.022","topics":["Treatment"],"weight":1,"_version_":1666428892729049088,"score":66.69044},{"pmid":32479246,"title":"Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.","text":["Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.","A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus disease 2019 (COVID-19). With the rapid increase of infected patients and deaths, it is urgent to explore an effective treatment for COVID-19. Current studies suggest that there exists cytokine storm in SARS-CoV-2-infected patient, some of the patients will develop to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction, even death. Mesenchymal stem cells (MSCs) possess the property of immunomodulation. Given the previous preclinical and clinical studies, MSCs therapy has been shown safety and efficacy in the treatment of respiratory failure or ARDS. Based on similar principles, MSCs therapy may also be an effective therapy in the treatment of COVID-19. In this study, we summarized the clinical outcomes of MSCs for ARDS patients in some preclinical and clinical studies, and discussed the application of MSCs for patients with COVID-19 in China and the related important issues with MSCs use during the outbreak.","Curr Stem Cell Res Ther","Xiong, Jing","Bao, Lei","Qi, Hongbo","Feng, Zhichun","Shi, Yuan","32479246"],"abstract":["A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus disease 2019 (COVID-19). With the rapid increase of infected patients and deaths, it is urgent to explore an effective treatment for COVID-19. Current studies suggest that there exists cytokine storm in SARS-CoV-2-infected patient, some of the patients will develop to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction, even death. Mesenchymal stem cells (MSCs) possess the property of immunomodulation. Given the previous preclinical and clinical studies, MSCs therapy has been shown safety and efficacy in the treatment of respiratory failure or ARDS. Based on similar principles, MSCs therapy may also be an effective therapy in the treatment of COVID-19. In this study, we summarized the clinical outcomes of MSCs for ARDS patients in some preclinical and clinical studies, and discussed the application of MSCs for patients with COVID-19 in China and the related important issues with MSCs use during the outbreak."],"journal":"Curr Stem Cell Res Ther","authors":["Xiong, Jing","Bao, Lei","Qi, Hongbo","Feng, Zhichun","Shi, Yuan"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479246","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.2174/1574888X15666200601152832","keywords":["mesenchymal stem cells","acute respiratory distress syndrome","coronavirus disease 2019"],"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1668532089573605376,"score":63.69642}]}